APONTIS PHARMA continues to gear organization towards growth and
internationalization - Renowned industry expert leads supply chain management

EQS-News: APONTIS PHARMA AG / Key word(s): Personnel
APONTIS PHARMA continues to gear organization towards growth and
internationalization - Renowned industry expert leads supply chain
management

04.06.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

APONTIS PHARMA continues to gear organization towards growth and
internationalization - Renowned industry expert leads supply chain
management

* Mila Brückel appointed as Head of Supply Chain

  * Extensive expertise in managing global supply chain programs from
    positions at Merck Healthcare

Monheim / Rhein, 4 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN
DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill
combinations in the German market, continues to gear its organization
towards the planned company growth and the upcoming internationalization. To
this end, the Company has appointed Mila Brückel, a renowned industry expert
and supply chain specialist, as Head of Supply Chain.

Since 3 June 2024, Mila Brückel has been responsible for all aspects of
supply chain management at APONTIS PHARMA, including demand forecasting,
procurement, inventory management, new product launches, and distribution to
customers. In her new role, she reports directly to CEO Bruno Wohlschlegel.

Mila Brückel has more than 25 years of experience in supply chain management
- including 15 years in the pharmaceutical sector - and joins APONTIS PHARMA
from Merck Healthcare, the healthcare segment of Merck KGaA, a leading
global pharmaceutical and chemical company. There she was Head of Supply
Chain for the German pharmaceutical business and before that responsible for
the global supply chain of General Medicine Classics and diabetes products,
among other things. Prior to Merck Healthcare, Mila Brückel was responsible
for the supply chain at Airwell Germany.

Bruno Wohlschlegel, CEO of APONTIS PHARMA: "Mila Brückel is a renowned
expert in supply chain management in the pharmaceutical industry. With her
appointment, we are taking this area of our company to a new level by adding
top-class talent. Mila's experience in managing global supply chain programs
will help us to optimally align our increasingly complex product portfolio
with demand and prepare us for the challenges of our upcoming
internationalization. I look forward to working with her."

Additional information:

Information on upcoming events can be found at
https://apontis-pharma.de/en/financial-calendar and the latest analyst
assessments at https://apontis-pharma.de/en/share-price.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single
Pill combinations in Germany. Single Pills combine two to three generic
active ingredients in a single dosage form administered once a day. Single
Pill therapies have been scientifically proven to significantly increase
adherence and thus improve the treatment prognosis and quality of life of
patients while reducing complications, mortality, and treatment costs.
Consequently, Single Pill combinations are the preferred treatment option in
numerous international treatment guidelines, including in the EU and
Germany. APONTIS PHARMA has been developing, promoting, and distributing a
broad portfolio of Single Pill combinations and other pharmaceutical
products since 2013, with a special focus on cardiovascular diseases such as
hypertension, hyperlipidemia, and secondary prevention. For additional
information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330


---------------------------------------------------------------------------

04.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        APONTIS PHARMA AG
                   Alfred-Nobel-Str. 10
                   40789 Monheim
                   Germany
   E-mail:         ir@apontis-pharma.de
   Internet:       https://apontis-pharma.de/
   ISIN:           DE000A3CMGM5
   WKN:            A3CMGM
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt (Scale), Munich, Stuttgart, Tradegate
                   Exchange
   EQS News ID:    1916507

End of News EQS News Service
---------------------------------------------------------------------------

1916507 04.06.2024 CET/CEST